tbuckley/cabot-search huggingface dataset:
For Our Patients, Not for Profits
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomized Phase Ii Study of Concurrent Versus Sequential Alternating Gefitinib and Chemotherapy in Previously Untreated Non-Small Cell Lung Cancer (Nsclc) with Sensitive Egfr Mutations: Nej005/Tcog0902
Authors: O. Ishimoto, S. Oizumi, K. Minato, T. Harada, A. Inoue, Y. Fujita, M. Maemondo, H. Yoshizawa, K. Ito, A. Gemma, M. Nishitsuji, M. Harada, H. Isobe, I. Kinoshita, S. Morita, K. Kobayashi, K. Hagiwara, M. Kurihara, T. Nukiwa
Journal: Annals of Oncology (2014)
Hydroxylation of Guanine in Nucleosides and DNA at the C-8 Position by Heated Glucose and Oxygen Radical-Forming Agents
Authors: Hiroshi Kasai, Susumu Nishimura
Journal: Environmental Health Perspectives (1986)

Heated glucose is mutagenic to Salmonella typhimurium TA 100 in the absence of S-9 mix. For identifying unknown mutagens in heated glucose (dry solid, 200 degrees C, 20 min), reaction with isopropylideneguanosine (IPG) was followed by isolation and characterization of the mutagen-IPG adduct. Two adducts, glyoxal-IPG and 8-hydroxy-IPG, were identified in the reaction mixture by this technique. To elucidate the mechanism of this hydroxylation reaction, we investigated the abilities of various agents to hydroxylate deoxyguanosine or guanine base in DNA. Various reducing agents, metals, asbestoses, polyphenols, aminophenols, and X-ray were effective for hydroxylation, and an oxygen radical seems to be the reactive species. For sensitive detection of 8-hydroxyguanine, a monoclonal antibody for it was prepared.
PROOF OF ABORTION BY CIRCUMSTANTIAL EVIDENCE.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria
Journal: American Journal of Respiratory and Critical Care Medicine (1997)

Diagnostic criteria of nontuberculous mycobacterial lung disease in HIV-seropositive and -seronegative hosts. The following criteria apply to symptomatic patients with infiltrate, nodular or cavitary disease, or a high resolution computed tomography scan that shows multifocal bronchiectasis and/or multiple small nodules. A. If three sputum/bronchial wash results are available from the previous 12 mo: 1. three positive cultures with negative AFB smear results or 2. two positive cultures and one positive AFB smear B. If only one bronchial wash is available: 1. positive culture with a 2+, 3+, or 4+ AFB smear or 2+, 3+, or 4+ growth on solid media C. If sputum/bronchial wash evaluations are nondiagnostic or another disease cannot be excluded: 1. transbronchial or lung biopsy yielding a NTM or 2. biopsy showing mycobacterial histopathologic features (granulomatous inflammation and/or AFB) and one or more sputums or bronchial washings are positive for an NTM even in low numbers.these criteria fit best with M. avium complex, M. abscessus, and M. kansasii. Too little is known of other NTM to be certain how applicable these criteria will be. At least three respiratory samples should be evaluated from each patient. Other reasonable causes for the disease should be excluded. Expert consultation should be sought when diagnostic difficulties are encountered.
MEDICAL DEFICIENCY IN THE SOUTH AFRICAN WAR.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Altered NMDA Glutamate Receptor Antagonist Response in Individuals With a Family Vulnerability to Alcoholism
Authors: I. L. Petrakis
Journal: American Journal of Psychiatry (2004)

OBJECTIVE: A family history of alcoholism is a risk factor for the development of ethanol dependence. Ethanol is an antagonist of the N-methyl-d-aspartate (NMDA) glutamate receptor, and alterations in NMDA receptor function are thought to be involved in ethanol abuse and dependence. The purpose of this study was to determine in healthy individuals with no ethanol dependence whether response to the NMDA receptor antagonist ketamine would differentiate those with a family history of ethanol dependence from those without such a family history. METHOD: Healthy subjects between the ages of 21 and 30 received 40-minute intravenous infusions of saline, low-dose ketamine (0.1 mg/kg), and high-dose ketamine (0.5 mg/kg) on three separate test days in a randomized order under double-blind conditions. The healthy individuals with at least one first-degree relative and another first- or second-degree relative with ethanol dependence (N=16) were compared with those who had no family history of ethanol dependence in any first- or second-degree relative (N=29). Outcome measures included the Brief Psychiatric Rating Scale, Clinician-Administered Dissociative States Scale, verbal fluency, Hopkins Verbal Learning Test, a biphasic alcohol effects scale, visual analog scales of mood states, and ketamine levels. RESULTS: During ketamine infusion, individuals with a family history of ethanol dependence showed an attenuated response in terms of perceptual alterations and dysphoric mood relative to those without such a family history. CONCLUSIONS: These data suggest that alterations in NMDA receptor function may contribute to subjective response to ethanol and therefore also to the risk of developing alcoholism.
Clinical Pediatrics, Philadelphia
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JAMA 75 YEARS AGO
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A randomized controlled trial of a novel artificial-intelligence based smartphone application to optimize the management of cancer-related pain.
Authors: Mihir M. Kamdar, Amanda Jayne Centi, Nils Fischer, Kamal Jethwani
Journal: Journal of Clinical Oncology (2018)

76 Background: Cancer pain affects 70-90% of advanced malignancy patients, resulting in impaired quality of life and increased healthcare utilization. Novel care delivery models are needed to optimize care for patients dealing with cancer-related pain in between clinic visits. ePAL is a smartphone application(app) that regularly monitors pain and uses artificial intelligence(AI) to differentiate urgent from non-urgent issues to intercede in real time. The purpose of this randomized controlled trial was to determine ePAL's impact on pain severity, attitudes toward cancer treatment, and healthcare utilization in patients with cancer pain. Methods: MGH Palliative Care Clinic Patients with pain from metastatic, solid-organ cancer (n=112) were recruited and randomized to either a control group (n=56) that received usual care or an intervention group (n=56) that used the ePAL app in addition to usual care for 8 weeks. The app assessed pain 3 times/week and questionnaires about pain (BPI), attitudes towards cancer treatment(BQ-II), and general anxiety(GAD-7) were given at 0, 4, and 8 weeks. A repeated measures mixed model approach assessed how outcome measures changed over time. Models controlled for baseline differences at enrollment and random slopes in addition to baseline depression score, age and sex(alpha=0.05). Results: Pain severity (BPI) and negative attitudes toward cancer pain treatment (BQ-II) decreased significantly for those using the app compared to controls(coeff. -0.09, 95% CI: -0.17, -0.007, p=0.034 and coeff. -0.037, 95% CI: -0.072, -0.001, p=0.042 respectively). Anxiety scores increased for those using ePAL compared to controls (coeff. 0.21, 95% CI: 0.039, 0.37, p=0.015). Over 8-weeks, ePAL users had 40% fewer inpatient hospital admissions compared to controls (n=15 vs. n=25, p=0.048). Conclusions: To our knowledge, this is the first mobile app to utilize AI and clinical algorithms to significantly decrease pain and reduce overall inpatient hospitalizations in patients with cancer-related pain. Clinical trial information: NCT02069743.
Prism in Spring
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comments and Critiques on the EMBRACE Health Care Reform Plan
Authors: Quentin D. Young
Journal: Annals of Internal Medicine (2009)

Letters3 November 2009Comments and Critiques on the EMBRACE Health Care Reform PlanQuentin D. Young, MDQuentin D. Young, MDFrom Physicians for a National Health Program, Chicago, IL 60602.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-9-200911030-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Although the objectives of providing universal coverage, reducing administrative costs, and building on the public financing of health care are laudable, the proposal by Lancaster and colleagues (1) for a 3-tiered health insurance system is fatally flawed.Dividing the population's health coverage into tiers—a major share of which is to be controlled by for-profit, private insurers—would perpetuate the wasteful fragmentation of our dysfunctional system. Such multipayer inefficiency would continue to deny us the vast administrative savings achievable only under a single-payer plan.The proposal's vague language differentiating the basic, publicly financed level of care (Tier 1, covering ...References1. Lancaster GI, O'Connell R, Katz DL, Manson JE, Hutchison WR, Landau C, et al; Healthcare Professionals for Healthcare Reform. The expanding medical and behavioral resources with access to care for everyone health plan. Ann Intern Med. 2009;150:490-2. [PMID: 19258548] LinkGoogle Scholar2. Carroll AE, Ackerman RT. Support for National Health Insurance among U.S. Physicians: 5 years later [Letter]. Ann Intern Med. 2008;148:566-7. [PMID: 18378959] LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Quentin D. Young, MDAffiliations: From Physicians for a National Health Program, Chicago, IL 60602.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSupport for National Health Insurance among U.S. Physicians: 5 Years Later Aaron E. Carroll and Ronald T. Ackerman The Expanding Medical and Behavioral Resources with Access to Care for Everyone Health Plan Gilead I Lancaster , Ryan O'Connell , David L. Katz , JoAnn E. Manson , William R. Hutchison , Charles Landau , Kimberly A. Yonkers , and Comments and Critiques on the EMBRACE Health Care Reform Plan Richard L. O'Brien and Donald Frey Comments and Critiques on the EMBRACE Health Care Reform Plan Christopher K. Johnson Comments and Critiques on the EMBRACE Health Care Reform Plan Gary R. Gibson Comments and Critiques on the EMBRACE Health Care Reform Plan Gilead I. Lancaster , Ryan O'Connell , and David L. Katz Metrics 3 November 2009Volume 151, Issue 9Page: 670-671KeywordsConflicts of interestHealth careHealth insuranceLong-term careMedicarePatientsPrevention, policy, and public healthQuality of life ePublished: 3 November 2009 Issue Published: 3 November 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Prenatal screening for neural tube defects
Authors: J. E. Haddow
Journal: JAMA (1979)

NEURAL tube defects, including anencephaly and spina bifida, are among the commonest major congenital malformations in the United States.<sup>1</sup>A study in selected Massachusetts hospitals disclosed a combined prevalence rate of 2.24 per 1,000 births during the years 1930 to 1965.<sup>2</sup>Between 1972 and 1975, twenty-six neural tube defects were found among 18,155 consecutive deliveries at the Boston Hospital for Women (1.43 per 1,000).<sup>3</sup>The Center for Disease Control in Atlanta reported an incidence of 2.35 per 1,000 for the white population and 0.9 per 1,000 for the black population.<sup>4</sup>Among the first 6,031 pregnancies screened in Nassau County, NY, ten neural tube defects were prospectively identified. Women who have been delivered of a conceptus with one of these lesions are at approximately 2% risk of having another similarly affected offspring in each succeeding pregnancy.<sup>3</sup>In a given year, however, more than 90% of all
G-6-PD deficiency, sickle cell trait, and acute hemolysis after bronchography
Authors: R. L. Richardson
Journal: JAMA (1969)

Acute hemolysis in a patient with sickle cell trait and glucose-6-phosphate-dehydrogenase deficiency was observed following a bronchogram with a sulfa-containing medium. We believe the acute episode was precipitated by the combination of hypoxia during the procedure and the ingestion of sulfa compound.
Phase I study of oxaliplatin (Ox), irinotecan (Irino), and capecitabine (Cape) in patients with solid tumors
Authors: S. S. Krishnamurthi, J. M. Brell, K. M. Coviello, A. Dowlati, M. J. Egorin, C. L. Hoppel, S. T. Ingalls, S. P. Ivy, X. Li, S. C. Remick
Journal: Journal of Clinical Oncology (2004)

2111 Background: The combination of Ox, Irino and Cape has high potential for activity in gastrointestinal malignancies. Methods: Patients (pts) had solid tumors not amenable to curative therapy. Treatment: Ox intravenous (IV) days 1,8,15,22, followed by Irino IV days 1,8,15,22, and Cape orally bid Monday-Friday weeks1–4, repeated every 6 weeks. Primary endpoints: maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and pharmacokinetic (PK) analysis. Response assessed q 2 cycles. Results: (see table) 22 pts enrolled: 13 males; median age 60, range 38–80; 11 colorectal cancer (ca); median 2 prior regimens. DLT at initial dose level 1A led to a protocol amendment lowering Cape dose. Peak SN38 concentrations of 10 ng/ml exceeded the IC50 doses reported for KB and L1210 tumor cells (0.37 and 3.6 ng/ml) (Kaneda, Cancer Res 1990). The mean peak ultrafilterable platinum was 0.75 +/- 0.17 μg/ml, exceeding the 0.5 μg/ml Ox concentration at which antitumor activity was observed against colon cancer using a human tumor cloning assay (Von Hoff, Clin Cancer Res 1998). Of 16 evaluable pts there was 1 complete response (gastric ca, prior 5-FU/radiation) and 8 with stable disease, including 6 with freedom from progression for ≥ 6 months. Conclusions: The recommended phase II dose is dose level 3. Preliminary PK parameters appear consistent with cytotoxic concentrations in pre-clinical models. This regimen is active in a pre-treated population. (Supported by NIH grants UO1 CA 62502–10 and MO1 RR000080, General Clinical Research Center.) Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pfizer; Sanofi Pfizer Pfizer
HUGH OWEN THOMAS (1834-1891) RUSTIC ORTHOPEDIST
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Observations on Analysis of Ten Thousand Urinary Calculi
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal